Business
Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting
Two oral presentations and three poster presentations elucidate new data relevant to rusfertide, a hepcidin mimetic with potential therapeutic value in the
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":"Two oral presentations and three poster presentations elucidate new data relevant to rusfertide, a hepcidin mimetic with potential therapeutic value in the treatment of Polycythemia Vera and other disease indicationsNEWARK, CA / ACCESSWIRE / November 2, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) (\"Protagonist\" or \"the Company\") announced today that five abstracts relevant to the Company's rusfertide program have been accepted for presentation at the 65th American Society of Hematology Annual Meeting and Exposition (ASH), taking place December 9-12, 2023 in San Diego, California.\"We are extremely pleased to present a broad cross-section of new data at ASH this year,\" said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist. \"Among these presentations are data which underscore the potential for rusfertide to improve markers of iron deficiency in polycythemia vera, and to sustain improved outcomes such as hematocrit control in PV patients over a two-year time horizon.Additionally, we look forward to sharing data that elucidate important epidemiological aspects of PV, drawing upon an extensive analysis of claims data and other resources. Finally, we look forward to presenting new preclinical data demonstrating improved disease parameters with a hepcidin mimetic treatment in a mouse model for sickle cell disease.\"Dr. Patel continued: \"Congratulations to our internal team and external partners for the dedication and rigor they have applied to these important areas of scientific research. Taken together, these presentations constitute major contributions to the field of hematology.\"Oral presentation details are as follows:Oral Presentation 1:Title: Real-World Analysis of Thromboembolic Event Rates in Patients in the United States with Polycythemia VeraPresenting author: Andrew T. Kuykendall, MD (Moffitt Cancer Center, Tampa, FL)Session Name: 904. Outcomes Research - Non-Malignant Conditions: Across the Age Spectrum: Thromboembolism Outcomes in Adult and Pediatric PatientsSession Date: Saturday, December 9, 2023Session Time: 9:30-11:00 AM PSTPresentation Time: 10:30 AM PSTRoom: Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19Publication Number: 137Submission ID: 180309Oral Presentation 2:Title: Durability of Hematocrit Control in Polycythemia Vera with the First-in-Class Hepcid...